| http://www.w3.org/ns/prov#value | - sai-VTE, are the largest comparative trials of a novel oral anticoagulant in these patient populations, involving 21,105 and 8,292 patients, respectively.1,2The submission of our MAA in Europe for edoxaban represents our long standing commitment to addressing the needs of patients living with cardiovascular diseases, including AF or VTE, said Glenn Gormley, MD, PhD, Senior Executive Officer and
|
